你即將離開本站

並前往https://adisinsight.springer.com/drugs/800050247

AK 103 - AdisInsight - Springer

Akeso Biopharma is developing AK 103, an anti-programmed death 1 (PD-1) antibody, for the treatment of immuno-oncology indications. Phase I development is.

確定！ 回上一頁

查詢 「AK 103」的人也找了：

  1. AK 104
    2.
  2. AK12
    3.
  3. ak-12
    4.
  4. AK-19
    5.
  5. kr-103
    6.
  6. AKM
    7.
  7. ak家族
    8.
  8. Type 56
    9.